| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00345-003-0363-Y |
| P698 | PubMed publication ID | 12920560 |
| P50 | author | Spencer J. Collis | Q55303040 |
| P2093 | author name string | Theodore L DeWeese | |
| Kevin Khater | |||
| P2860 | cites work | Site-specific integration by adeno-associated virus | Q24558738 |
| Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells | Q27860926 | ||
| RNA interference | Q28131798 | ||
| Oncolytic herpes simplex virus vectors for cancer virotherapy | Q28202611 | ||
| Post-transcriptional gene silencing by double-stranded RNA | Q28205087 | ||
| Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1 | Q28210476 | ||
| Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells | Q28215061 | ||
| Metastasis to bone: causes, consequences and therapeutic opportunities | Q29614310 | ||
| In vivo protein transduction: delivery of a biologically active protein into the mouse | Q29615482 | ||
| Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer | Q30310656 | ||
| The National Cancer Data base Report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S. | Q30583616 | ||
| Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer | Q31045537 | ||
| Construction of a directed hammerhead ribozyme library: towards the identification of optimal target sites for antisense-mediated gene inhibition | Q31982706 | ||
| Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel | Q32046446 | ||
| Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats | Q33183242 | ||
| In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. | Q33328885 | ||
| Role of RNase H in hybrid-arrested translation by antisense oligonucleotides | Q33631283 | ||
| The early region 4 orf4 protein of human adenovirus type 5 induces p53-independent cell death by apoptosis | Q33783779 | ||
| Sensible use of antisense: how to use oligonucleotides as research tools | Q33818938 | ||
| Ad5CMVp53 gene therapy for locally advanced prostate cancer--where do we stand? | Q33943092 | ||
| Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. | Q34005910 | ||
| CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. | Q34084006 | ||
| Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer | Q34106818 | ||
| Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity | Q34130442 | ||
| Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015. | Q34136649 | ||
| Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site | Q34176217 | ||
| Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? | Q34225918 | ||
| Is alpha/beta for prostate tumors really low? | Q34294994 | ||
| Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas | Q34297434 | ||
| RNA interference: listening to the sound of silence | Q34347832 | ||
| Radiation therapy for the treatment of locally advanced and metastatic prostate cancer | Q34348253 | ||
| Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity | Q34364533 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. | Q34430883 | ||
| Implication of cell kinetic changes during the progression of human prostatic cancer | Q42725041 | ||
| High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation | Q42799808 | ||
| Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice | Q42816298 | ||
| Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. | Q42820783 | ||
| RNA interference in adult mice. | Q43038702 | ||
| Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy. | Q43550588 | ||
| Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer | Q43586837 | ||
| A radiation-controlled molecular switch for use in gene therapy of cancer. | Q43685592 | ||
| The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation | Q43688225 | ||
| Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy | Q43703244 | ||
| Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts | Q43719909 | ||
| A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin | Q43719922 | ||
| Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene | Q43917987 | ||
| Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial | Q44070350 | ||
| Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer | Q44123699 | ||
| Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. | Q44130120 | ||
| Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model | Q44177727 | ||
| Manganese superoxide dismutase gene therapy protects against irradiation-induced cystitis | Q44212463 | ||
| Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. | Q44220727 | ||
| Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. | Q44232574 | ||
| Ribozyme-mediated inhibition of PKCalpha sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis | Q44259379 | ||
| In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy | Q44269918 | ||
| Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. | Q44387424 | ||
| A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. | Q44845726 | ||
| Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer | Q44873808 | ||
| A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy | Q45247385 | ||
| Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors | Q45299117 | ||
| Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation | Q45733161 | ||
| Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates | Q45737125 | ||
| Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207. | Q45739297 | ||
| Fractionation and protraction for radiotherapy of prostate carcinoma | Q77227878 | ||
| Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer | Q77321070 | ||
| Liposome-encapsulated tumor necrosis factor-alpha enhances the effects of radiation against human colon tumor xenografts | Q77362756 | ||
| Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis | Q77424028 | ||
| Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue | Q77451468 | ||
| Herpes simplex virus | Q77678102 | ||
| Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin | Q78358440 | ||
| Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial | Q78365368 | ||
| A tragic setback | Q78516025 | ||
| Lentiviral-mediated RNA interference | Q40675408 | ||
| Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice | Q40678035 | ||
| Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex | Q40717443 | ||
| Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. | Q40735382 | ||
| Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors | Q40763368 | ||
| Development of synthetic promoters for radiation-mediated gene therapy | Q40770533 | ||
| Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation | Q40836669 | ||
| Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase | Q40920540 | ||
| Menage à trois: double strand break repair, V(D)J recombination and DNA-PK. | Q40925823 | ||
| A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells | Q40935663 | ||
| Potential benefit of improved local tumor control in patients with prostate carcinoma | Q40988074 | ||
| Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics | Q41060593 | ||
| Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times | Q41144469 | ||
| Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. | Q41563742 | ||
| The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. | Q41690221 | ||
| An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. | Q41694333 | ||
| The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. | Q41736480 | ||
| A good antisense molecule is hard to find | Q41736928 | ||
| Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines | Q41814575 | ||
| Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer | Q42353164 | ||
| Modulation of innate immunological factors by STEALTH liposome-encapsulated tumor necrosis factor-alpha in a colon tumor xenograft model. | Q42521473 | ||
| Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. | Q42524846 | ||
| Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials | Q34452020 | ||
| Molecular approaches to chemo-radiotherapy. | Q34501927 | ||
| Adenoviral gene therapy | Q34537888 | ||
| ONYX-015. Onyx Pharmaceuticals | Q34562778 | ||
| Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells | Q34591429 | ||
| Targeted adenoviral vectors | Q34646701 | ||
| Cancer gene therapy: 'delivery, delivery, delivery' | Q34667233 | ||
| Adenoviral vector-mediated gene transfer for human gene therapy | Q34729274 | ||
| Gene therapy of prostate cancer: current and future directions | Q34744823 | ||
| Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy | Q34786857 | ||
| Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy | Q34791438 | ||
| Antisense therapy: current status in prostate cancer and other malignancies | Q34980551 | ||
| Antisense therapy for cancer--the time of truth | Q34992794 | ||
| Replication-defective genomic herpes simplex vectors: design and production | Q35012883 | ||
| Liposomal delivery of nucleic acids in vivo | Q35062247 | ||
| In vivo DNA electrotransfer | Q35062251 | ||
| Adenovirus and adeno-associated virus vectors | Q35062259 | ||
| Gene delivery using herpes simplex virus vectors | Q35062264 | ||
| Lentiviral vectors for gene delivery into cells | Q35062267 | ||
| Progress and prospects: naked DNA gene transfer and therapy | Q35079580 | ||
| Therapeutic targets for metastatic prostate cancer | Q35087863 | ||
| Modulation of cellular function by TAT mediated transduction of full length proteins | Q35100870 | ||
| TAT peptide internalization: seeking the mechanism of entry. | Q35100881 | ||
| The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells | Q35858778 | ||
| Attenuation of DNA-dependent protein kinase activity and its catalytic subunit by the herpes simplex virus type 1 transactivator ICP0. | Q35871672 | ||
| Ribozyme-mediated reversal of the multidrug-resistant phenotype | Q35897342 | ||
| Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection | Q36720691 | ||
| The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins | Q37162513 | ||
| Ribozyme-mediated downregulation of human metallothionein II(a) induces apoptosis in human prostate and ovarian cancer cell lines | Q38292701 | ||
| Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells | Q38302961 | ||
| Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation | Q38307060 | ||
| Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. | Q38456204 | ||
| Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. | Q39548922 | ||
| Impact of improved local control on survival | Q39731992 | ||
| Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report | Q40595026 | ||
| Cancer fears cast doubts on future of gene therapy | Q40603071 | ||
| Expression of the DNA-PK binding protein E4-34K fails to confer radiation sensitivity to mammalian cells. | Q40607889 | ||
| Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses | Q40632608 | ||
| Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. | Q45747082 | ||
| The role of herpes simplex virus glycoproteins in the virus replication cycle. | Q45753486 | ||
| Vaccinia virus for human gene therapy. | Q45755568 | ||
| A cascade of adenovirus early functions is required for expression of adeno-associated virus | Q45800850 | ||
| Regulated expression of diphtheria toxin in prostate cancer cells | Q45855448 | ||
| Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results | Q45857349 | ||
| Gene therapy. Seeking the cause of induced leukemias in X-SCID trial | Q45858033 | ||
| Cell phenotype specific kinetics of expression of intratracheally injected manganese superoxide dismutase-plasmid/liposomes (MnSOD-PL) during lung radioprotective gene therapy | Q45858427 | ||
| Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. | Q45858661 | ||
| Gene silencing by adenovirus-delivered siRNA. | Q45859505 | ||
| Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules | Q45866282 | ||
| T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. | Q45866838 | ||
| Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. | Q45872927 | ||
| Overexpression of manganese superoxide dismutase (MnSOD) in whole lung or alveolar type II cells of MnSOD transgenic mice does not provide intrinsic lung irradiation protection | Q45875403 | ||
| Prostate-specific targeting using PSA promoter-based lentiviral vectors | Q45880320 | ||
| Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. | Q45881811 | ||
| Radioprotection of lung and esophagus by overexpression of the human manganese superoxide dismutase transgene. | Q45883867 | ||
| rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice | Q45886543 | ||
| Expression of ribozymes in gene transfer systems to modulate target RNA levels | Q45890110 | ||
| BCL2 antisense reduces prostate cancer cell survival following irradiation. | Q46014956 | ||
| Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents | Q46061653 | ||
| Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review). | Q47614304 | ||
| Trojan peptides: the penetratin system for intracellular delivery | Q47721580 | ||
| Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. | Q53773145 | ||
| System for robotically assisted prostate biopsy and therapy with intraoperative CT guidance. | Q53876538 | ||
| Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody. | Q54095850 | ||
| Virus-mediated killing of cells that lack p53 activity | Q59098652 | ||
| Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin | Q59364974 | ||
| A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus | Q63343005 | ||
| Stepwise dismantling of adenovirus 2 during entry into cells | Q64377608 | ||
| Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo | Q64377981 | ||
| In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer--changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile | Q64379741 | ||
| 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells | Q68190354 | ||
| Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314 | Q69615425 | ||
| Age-related changes in the activities of antioxidant enzymes and lipid peroxidation status in ventral and dorsolateral prostate lobes of noble rats | Q71160071 | ||
| An uncertain role for p53 gene alterations in human prostate cancers | Q71254302 | ||
| Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group | Q72156114 | ||
| Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue | Q72851913 | ||
| A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme | Q73022564 | ||
| Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers | Q73456912 | ||
| Expression of antioxidant enzymes in human prostatic adenocarcinoma | Q73676423 | ||
| Cell-cycle arrest versus cell death in cancer therapy | Q73677622 | ||
| Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo | Q73803349 | ||
| Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors | Q73856260 | ||
| Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer | Q74300566 | ||
| Efficient delivery of siRNA for inhibition of gene expression in postnatal mice | Q74531314 | ||
| Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure | Q74738676 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adaptive radiation therapy | Q180507 |
| prostate cancer | Q181257 | ||
| gene therapy | Q213901 | ||
| P304 | page(s) | 275-289 | |
| P577 | publication date | 2003-08-13 | |
| P1433 | published in | World Journal of Urology | Q15750774 |
| P1476 | title | Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy | |
| P478 | volume | 21 |
| Q40488102 | Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer |
| Q45880240 | Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas. |
| Q36429405 | The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck |
| Q24811943 | U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3. |
Search more.